SMO and skin basal cell carcinoma: Studies of tumorigenesis mediated by HH signaling activation have recently culminated in the USA Food and Drug Administration’s (FDA) approval of GDC-0449 (vismodegib) [6], an oral inhibitor of the HH signaling mediator, Smoothened (SMO), as a therapeutic for treating advanced or metastatic BCC.